ScoreWhy is Ajanta Pharma Ltd. ?
1
High Management Efficiency with a high ROE of 22.14%
2
Company has a low Debt to Equity ratio (avg) at 0 times
3
Poor long term growth as Net Sales has grown by an annual rate of 13.54% and Operating profit at 6.72% over the last 5 years
4
Flat results in Mar 26
- DEBTORS TURNOVER RATIO(HY) Lowest at 2.94 times
5
Stock is technically in a Bullish range
- The technical trend has improved from Mildly Bullish on 12-May-26
- Multiple factors for the stock are Bullish like MACD, Bollinger Band and OBV
6
With ROE of 23.3, it has a Expensive valuation with a 8.6 Price to Book Value
- The stock is trading at a fair value compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 19.64%, its profits have risen by 14.7% ; the PEG ratio of the company is 2.5
7
High Institutional Holdings at 26.64%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
8
Consistent Returns over the last 3 years
- Along with generating 19.64% returns in the last 1 year, the stock has outperformed BSE500 in each of the last 3 annual periods
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to Ajanta Pharma should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Ajanta Pharma for you?
Medium Risk, High Return
Absolute
Risk Adjusted
Volatility
Ajanta Pharma
34.87%
0.74
26.50%
Sensex
-1.65%
-0.49
12.94%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
14.23%
EBIT Growth (5y)
8.05%
EBIT to Interest (avg)
97.07
Debt to EBITDA (avg)
Net Debt is too low
Net Debt to Equity (avg)
-0.09
Sales to Capital Employed (avg)
1.10
Tax Ratio
24.00%
Dividend Payout Ratio
33.24%
Pledged Shares
22.53%
Institutional Holding
29.48%
ROCE (avg)
29.63%
ROE (avg)
22.14%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
39
Industry P/E
37
Price to Book Value
9.69
EV to EBIT
33.67
EV to EBITDA
29.62
EV to Capital Employed
10.54
EV to Sales
7.52
PEG Ratio
1.76
Dividend Yield
1.71%
ROCE (Latest)
29.63%
ROE (Latest)
23.33%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Bullish
Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend17What is working for the Company
NET SALES(Q)
Highest at Rs 1,625.96 cr
PBDIT(Q)
Highest at Rs 423.58 cr.
PBT LESS OI(Q)
Highest at Rs 375.90 cr.
PAT(Q)
Highest at Rs 334.22 cr.
EPS(Q)
Highest at Rs 26.66
-5What is not working for the Company
OPERATING CF(Y)
Lowest at Rs 529.19 Cr
DEBTORS TURNOVER RATIO(HY)
Lowest at 2.94 times
Loading Valuation Snapshot...
Here's what is working for Ajanta Pharma
Net Sales - Quarterly
Highest at Rs 1,625.96 cr and Grown
each quarter in the last five quartersMOJO Watch
Near term sales trend is very positive
Net Sales (Rs Cr)
Net Sales - Quarterly
At Rs 1,625.96 cr has Grown at 24.82%
Year on Year (YoY)MOJO Watch
Near term sales trend is positive
Net Sales (Rs Cr)
Operating Profit (PBDIT) - Quarterly
Highest at Rs 423.58 cr.
in the last five quartersMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (Rs Cr)
Profit Before Tax less Other Income (PBT) - Quarterly
Highest at Rs 375.90 cr.
in the last five quartersMOJO Watch
Near term PBT trend is positive
PBT less Other Income (Rs Cr)
Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 375.90 cr has Grown at 23.33%
Year on Year (YoY)MOJO Watch
Near term PBT trend is positive
PBT less Other Income (Rs Cr)
Profit After Tax (PAT) - Quarterly
Highest at Rs 334.22 cr.
in the last five quartersMOJO Watch
Near term PAT trend is positive
PAT (Rs Cr)
Profit After Tax (PAT) - Quarterly
At Rs 334.22 cr has Grown at 30.9%
Year on Year (YoY)MOJO Watch
Near term PAT trend is positive
PAT (Rs Cr)
Earnings per Share (EPS) - Quarterly
Highest at Rs 26.66
in the last five quartersMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (Rs)
Here's what is not working for Ajanta Pharma
Operating Cash Flow - Annually
Lowest at Rs 529.19 Cr
in the last three yearsMOJO Watch
The company's cash revenues from business operations are falling
Operating Cash Flows (Rs Cr)
Debtors Turnover Ratio- Half Yearly
Lowest at 2.94 times
in the last five half yearly periodsMOJO Watch
Company's pace of settling its Debtors has slowed
Debtors Turnover Ratio
Non Operating Income - Quarterly
Highest at Rs 70.90 cr
in the last five quartersMOJO Watch
Increased income from non business activities may not be sustainable
Non Operating Income
